기본 정보
- CAS
98418-47-4- 표준 SMILES
COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)CCC(=O)O- InChIKey
RGHAZVBIOOEVQX-UHFFFAOYSA-N- 분자식
- C34H56N2O10
- 평균 분자량
- 652.8 g/mol
- 단동위원소 질량
- 652.39349599
개요
Metoprolol succinate is an alcohol and a member of phenols.
이름 및 식별자
- 우선 이름
- Metoprolol Succinate
- IUPAC
- butanedioic acid;bis(1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol)
- 현지명
- 메트로프롤롤숙신산
- 영어명
- Metroprolol succinate
- 분자식
- 2C15H25NO3.C4H6O4
- 분자량
- 652.82
이름 및 동의어
Metoprolol succinate98418-47-4SelozokToprol XLSeloken-ZOKMetoprolol hemisuccinateH 93/26 succinateTOPROL-XLDTXSID9048726TH25PD4CCBDTXCID6028652KAPSPARGO
이름 더 보기
메트로프롤롤숙신산rolol succinateMaetaprolol succinateMETOPROLOL SUCCINATE USPMetoprolol succinate BaseMetoprolol Succinate (200 mg)Metoprolol Succinate (ToprolX)
Metoprolol Succinate ERRefChem:55626KAPSPARGO SPRINKLEMetoprolol Succinate E/rMetoprolol Succinate ER TabletsMetoprolol Succinate Extended-releaseToprolMetroprolol succinate
데이터베이스 식별자
- CAS
98418-47-4- PubChem CID
- 62937
- DTXSID
DTXSID9048726- ChEMBL
CHEMBL2356097- ChEBI
CHEBI:6905- UNII
- TH25PD4CCB
- EC Number
물성
구조 계산 물성
- 극성 표면적
- 176 Ų
- 수소 결합 공여자 수
- 6
- 수소 결합 수용자 수
- 12
- 회전 가능 결합 수
- 21
- 무거운 원자 수
- 46
- 형식 전하
- 0
- 복잡도
- 308
실험 및 물리화학적 성질
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
물리화학적 성질
- 녹는점
- 136 · 136-138°C
- 저장 조건
- Hygroscopic, Refrigerator, under inert atmosphere
- 용해도
- 물에 잘 녹고, 메탄올에 녹고, 에탄올(96%)에 약간 녹고, 에틸 아세테이트에는 매우 녹습니다.
- 물리적 상태
- Solid
- 색상
- 흰색에서 황백색까지
- 안정성
- 흡습성
- InChI
- InChI=1S/2C15H25NO3.C4H6O4/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-3(6)1-2-4(7)8/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
- InChIKey
- RGHAZVBIOOEVQX-UHFFFAOYSA-N
- SMILES
- C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1.C(C(=O)O)CC(=O)O.C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1
화학적 성질
White or almost white, crystalline powder.
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
GHS 분류
GHS Classification
Danger
H302 (11.5%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P264, P270, P273, P301+P317, P308+P316, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 52 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
유해성 정보
Hazard Classes and CategoriesAcute Tox. 4 (11.5%)
독성 정보
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Metoprolol succinate
Ambiguous-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
안전 데이터
- HS 번호
- 2922190900
화학 및 산업
약리 정보
FDA Pharmacological Classification
METOPROLOL SUCCINATE
Adrenergic beta-Antagonists [MoA]; beta-Adrenergic Blocker [EPC]
METOPROLOL SUCCINATE ER
beta-Adrenergic Blocker [EPC]; Adrenergic beta-Antagonists [MoA]
METOPROLOL SUCCINATE ER TABLETS
Adrenergic beta-Antagonists [MoA]; beta-Adrenergic Blocker [EPC]
MeSH Pharmacological Classification
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.
응용 분야
역사Metoprolol Succinate, the world's first Beta-1 Selective Receptor blocker, was developed by AstraZeneca and first launched in 1992. It is commonly used in clinical practice to treat hypertension, angina pectoris, and stable chronic heart failure with impaired left ventricular systolic function.Metoprolol was first developed in 1969 at Hassle Laboratories in Sweden. As a selective beta-1 adrenergic receptor blocker, it binds to beta-1 receptors to antagonize the effects of neurotransmitters and catecholamines on beta receptors. This action increases vascular smooth muscle sensitivity to vasoactive mediators and inhibits renin secretion. Clinically, it is used to treat hypertension, angina pectoris, and heart failure.
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…